Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60, 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Tylski P, Stute S, Grotus N et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in 18F-FDG PET. J. Nucl. Med.51, 268–276 (2010).
   PubMedGoogle Scholar
• Czernin J, Schelbert H. PET/CT imaging: facts, opinions, hopes, and questions. J. Nucl. Med.45, 1–3 (2004).
   PubMedGoogle Scholar
• Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin. Nucl. Med.40, 283–293 (2010).
   PubMedGoogle Scholar
• Koehler L, Gagnon K, McQuerrie S et al. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules15, 2686–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J. Clin. Endocrinol. Metab.93, 1519–1525 (2008).
   PubMedGoogle Scholar
• Briele B, Hotze AL, Kropp J et al. A comparison of 201Tl and 99mtc-MIBI in the follow-up of differentiated thyroid carcinoma. Nuklearmedizin30, 115–124 (1991).
   PubMedGoogle Scholar
• Gorges R, Kahaly G, Muller-Brandt J et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in non-medullary thyroid cancer. Thyroid11, 647–659 (2001).
   PubMed Web of Science ®Google Scholar
• Blaser D, Maschauer S, Kuwert T et al. In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-iodide. J. Nucl. Med.47, 1382–1388 (2006).
   PubMedGoogle Scholar
• Spitzweg C, Joba W, Morris JC et al. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid9, 821–830 (1999).
   PubMedGoogle Scholar
• Russo D, Damante G, Foti D et al. Different molecular mechanisms are involved in the multihormonal control of glucose transport in FRTL5 rat thyroid cells. J. Endocrinol. Invest.17, 323–327 (1994).
   PubMedGoogle Scholar
• Grunwald F, Kalicke T, Feine U et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur. J. Nucl. Med.26, 1547–1552 (1999).
   PubMedGoogle Scholar
• Dietlein M, Scheidhauer K, Voth E et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med.24, 1342–1348 (1997).
   PubMedGoogle Scholar
• Conti PS, Durski JM, Bacqai F et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid9, 797–804 (1999).
   PubMed Web of Science ®Google Scholar
• Wang W, Macapinlac H, Larson SM et al. [18F]-2-fluoro-2-deoxy-D-Glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J. Clin. Endocrinol. Metab.84, 2291–2302 (1999).
   PubMed Web of Science ®Google Scholar
• Nahas Z, Goldenberg D, Fakhry C et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope115, 237–243 (2005).
   PubMed Web of Science ®Google Scholar
• Schluter B, Bohuslavizki KH, Beyer W et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J. Nucl. Med.42, 71–76 (2001).
   PubMedGoogle Scholar
• Alzahrani AS, Mohamed GE, Al Rifai A et al. Role of [18F] fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr. Pract.12, 15215–15218 (2006).
   Google Scholar
• Palmedo H, Bucerius J, Joe A et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J. Nucl. Med.47, 616–624 (2006).
   PubMedGoogle Scholar
• Finkelstein SE, Grigsby PW, Siegel BA et al. Combined [18F] Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann. Surg. Oncol.15, 286–292 (2008).
   PubMedGoogle Scholar
• Shammas A, Degirmenci B, Mountz JM et al.18F-FDG PET/CT in patients with suspected recurrent or metastatic well differentiated thyroid cancer. J. Nucl. Med.48, 221–226 (2007).
   PubMedGoogle Scholar
• Freudenberg LS, Frilling A, Kühl H et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur. Radiol.1, 3139–3147 (2007).
   Google Scholar
• Mirallié E, Guillan T, Bridji B et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery142, 952–958 (2007).
   PubMedGoogle Scholar
• Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur. J. Radiol.70, 17–24 (2008).
   PubMedGoogle Scholar
• Iagaru A, Kalinyak, Mc Dougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin. Nucl. Med.32, 690–695 (2007).
   PubMed Web of Science ®Google Scholar
• Menzel C, Zaplatnikov K, Diehl M, Döbert N, Hamscho N, Grünwald F. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl. Med. Commun.25, 239–243 (2004).
   PubMedGoogle Scholar
• Cooper DS, Doherty GM, Haugen BR et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid19, 1167–1214 (2009).
   PubMed Web of Science ®Google Scholar
• Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18FDG PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck doi:10.1002/hed.21791 (2011) (Epub ahead of print).
   Google Scholar
• Vera P, Kuhn-Lansoy C, Edet-Sanson A et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-Glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid2, 15–23 (2010).
   Google Scholar
• Gharib H, Papini E, Paschke R et al. American association of clinical endocrinologists, associazione medici endocrinologi and European thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. AACE/AME task force on thyroid nodules. Endocr. Pract.16(Suppl. 1), S1–S43 (2010).
   PubMed Web of Science ®Google Scholar
• Chao M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin. Oncolol. (R. Coll. Radiol.).22, 438–447 (2010).
   PubMedGoogle Scholar
• Kim WG, Ryu JS, Kim EY et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable thyroglobulin but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomograph scan. J. Clin. Endocrinol. Metab.95, 1169–1173 (2010).
   PubMedGoogle Scholar
• Leboulleux S, Schroeder PR, Busaidy NL et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-Glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J. Clin. Endocrinol. Metab.94, 1310–1316 (2009).
   PubMed Web of Science ®Google Scholar
• Ma C, Xie J, Lou Y et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobluin and negative scan: a meta-analysis. Eur. J. Endocrinol.163, 177–183 (2010).
   PubMedGoogle Scholar
• Lazar V, Bidart JM, Caillou B et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J. Clin. Endocrinol. Metab.84, 3228–3234 (1999).
   PubMed Web of Science ®Google Scholar
• Wang W, Larson SM, Fazzari M et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J. Clin. Endocrinol. Metab.85, 1107–1113 (2000).
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J. Clin. Endocrinol. Metab.91, 498–505 (2006).
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodéré F, Cariou B, Curtet C et al. Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. Surgery138, 1176–1182 (2005).
   PubMed Web of Science ®Google Scholar
• Phan HTT, Jager PL, Paans AMJ et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging35, 958–965 (2008).
   PubMedGoogle Scholar
• Freudenberg LS, Antoch G, Frilling A et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur. J. Nucl. Med. Mol. Imaging35, 950–957 (2008).
   PubMedGoogle Scholar
• Capoccetti F, Criscuoli B, Rossi G et al. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging53, 536–545 (2009).
   PubMedGoogle Scholar
• JentzenW, L Freudenberg, EG Eising et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J. Nucl. Med.49, 1017–1023 (2008).
   PubMedGoogle Scholar
• Freudenberg LS, Frömke C, Petrich T et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp. Clin. Endocrinol. Diabet.118, 393–399 (2010).
   PubMedGoogle Scholar